This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Biotech Trades for Second Half of 2011

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

YM BioSciences (YMI)
The event: Phase II study of CYT387 in myelofibrosis.
The timeline: Data at the American Society of Hematology (ASH) annual meeting, Dec. 10-13, 2011. An early peek at the CYT387 data could come in early November when ASH releases research abstracts for its annual meeting.
The stakes: YM BioSciences suffers from a credibility deficit. The company believes CYT387 is a best-in-class drug for myelofibrosis, capable of shrinking enlarged spleens, and most importantly reducing anemia without causing too many harmful side effects. Investors and potential partners want to see more data on CYT387 before they buy into YM Bioscience's story, which makes the ongoing phase II study critical for the company's future.

5 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BPAX $55.05 -1.24%
EXEL $2.83 -8.12%
GILD $102.94 -0.73%
ONTY $1.63 -6.32%
SGMO $13.34 -9.25%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs